KRAS Mutation Analysis

Synonyms	KRAS MUTATION ANALYSIS LAB14294
Cerner Name	HLX KRAS Mutation Analysis Case
Clinical Info	ASSAY DESCRIPTION: Kras mutations are detected in different cancers and can predict the response to EGFR inhibitors and guide patient treatment. This qualitative assay, performed on the Biocartis Idylla™ System using exclusively FFPE samples (Slides), detects 21 KRAS mutations in Codons 12, 13, 59, 61, 117 and 146 and does not detect mutations or alterations in other regions of the KRAS gene. LIMITATIONS: This assay is qualitative and is not intended to detect minimal residual disease. While covering codons 59 and 117, the assay does not distinguish between mutations occurring on the same nucleotide, i.e., A59E/G/T and A146P/T/V respectively. This assay is designed to detect Q61L (c.182A>T) mutation. Other rare or complex Q61L mutations might not be detected, except for Q61L 182_183AA>TT which is interpreted by the assay as a Q61H mutation. Mutations present below the limit of detection of the assay (5%) might not be detected.
Specimen Sources	Abdomen/Peritoneum Abscess Adenoids Adenoids Adrenal, Left Adrenal, Right Alopecia Amputation Anus Appendix Axilla, Left Axilla, Right Bile Duct Bladder Bone Bone Marrow Brain Breast, Left Breast, Right Bronchial, Left Bronchial, Right Catheter Cervix Colon Diaphragm Duodenum Ear, Left Ear, Right Endocervix Esophagus Extranodal Lymphoid Eye, Left Eye, Right Fallopian Tube, Left Fallopian Tube, Right Foreign Body Gallbladder Hardware/Implants Heart Hepatobiliary Duct Hernia Sac Hydrocele Ileum Jejunum Joint Kidney, Left Kidney, Right Larynx Liver Lung, Left Lung, Right Lymph Node Mandible Maxilla Mediastinum Meninges/Dura Misc Muscle Nail Nasal/Nasopharynx Nerve Ocular Omentum Oropharynx Oropharynx/Throat Ovary, Left Ovary, Right Pancreas Pancreas, Body Pancreas, Head Pancreas, Tail Pancreatic Duct Parathyroid, Left Parathyroid, Right Pelvic Penis Pericardium Pharynx Placenta Pleura, Left Pleura, Right Product of Conception Prostate Rectum Retroperitoneum Salivary Gland, Left Salivary Gland, Right Skin Soft Tissue Spinal Cord Spleen Stoma Stomach Synovium Testis, Left Testis, Right Thyroid, Isthmus Thyroid, Left Thyroid, Right Thyroid, Total Tongue Tonsil, Left Tonsil, Right Tooth Trachea Ureter, Left Ureter, Right Urethra Urine Uterus Vagina Vas Deferens, Left Vas Deferens, Right Vascular Vulva Wound Deep Wound/Skin Superficial Show more...
Specimen Types	Tissue
Specimen Volume	4x5 μm unstained FFPE slides and 1 H&E Slide.
Container	FFPE Slides
Collection Instructions	Specimen: 4 unstained 5um FFPE slides (each with an area 50-600 mm(2) are required. If the tumor content is less that 50 % please submit and additional H&E slide for macrodissection.
Transport Instructions
Specimen Stability	Room Temperature
Methodology	Qualitative Real-Time PCR performed on the Idylla(TM) platform
Days Performed	Monday - Friday
Performing Laboratories
CPT	81275,81276,88381
PDM	238468
Results
Result Interpretation Negative for KRAS Mutation Limitations This assay is qualitative and is not intended to detect minimal residual disease. While covering codons 59 and 117, the assay does not distinguish between mutations occurring on the same nucleotide, i.e., A59E/G/T and A146P/T/V respectively.This assay is designed to detect Q61L (c.182A>T) mutation. Other rare or complex Q61L mutations might not be detected, except for Q61L 182_183AA>TT which is interpreted by the assay as a Q61H mutation. Mutations present below the limit of detection of the assay (5%) might not be detected
Forms

Flow/Mol/Cytog - No Subgroup LAB14294